Not applicableUnknownNCT05750693What this trial is testingPIK3CA in HER2+ BC and pCR TrialWho this might be right forHER2-positive Breast Cancer Fondazione Policlinico Universitario Agostino Gemelli IRCCS 58
Not applicableStudy completedNCT04756921What this trial is testing18F-FDG Uptake Heterogeneity Predicts Pyrotinib ResponseWho this might be right forHER2-positive Breast Cancer Biyun Wang, MD 30
Testing effectiveness (Phase 2)UnknownNCT04170595What this trial is testingClinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for InjectionWho this might be right forHER2-positive Breast Cancer Genor Biopharma Co., Ltd. 132
Not applicableStudy completedNCT05458401What this trial is testingEUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab DeruxtecanWho this might be right forHER2-positive Breast Cancer Daiichi Sankyo 256
Large-scale testing (Phase 3)Looking for participantsNCT05646862What this trial is testingA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyWho this might be right forBreast Cancer Hoffmann-La Roche 420
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362What this trial is testingStudy BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesWho this might be right forUrinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more BicycleTx Limited 329
Large-scale testing (Phase 3)Active Not RecruitingNCT05002127What this trial is testingEvorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)Who this might be right forGastric CancerGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma ALX Oncology Inc. 127
Early research (Phase 1)Study completedNCT02476539What this trial is testingStudy Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast CancerWho this might be right forHER2 Positive Breast Cancer Tianjin Hemay Pharmaceutical Co., Ltd 28
Large-scale testing (Phase 3)Not Yet RecruitingNCT07153757What this trial is testingDe-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority TrialWho this might be right forBreast Cancer Early Stage Breast Cancer (Stage 1-3) Fudan University 2,934
Early research (Phase 1)Ended earlyNCT03429101What this trial is testingPoziotinib in Combination With T-DM1 in HER2-Positive Breast CancerWho this might be right forBreast Cancer Spectrum Pharmaceuticals, Inc 6
Testing effectiveness (Phase 2)Looking for participantsNCT04923542What this trial is testingSRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesWho this might be right forBrain MetastasesHR+ Metastatic Breast Cancer H. Lee Moffitt Cancer Center and Research Institute 31
Post-approval studies (Phase 4)UnknownNCT05131841What this trial is testingCipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBCWho this might be right forMetastatic Breast Cancer Zhejiang Cancer Hospital 60
Not applicableNot Yet RecruitingNCT07406594What this trial is testingGut Microbiome Changes During Abemaciclib Therapy in Breast CancerWho this might be right forBreast CancerHER-2 Positive Breast Cancer University of Vermont Medical Center 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04538742What this trial is testingA Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer AstraZeneca 245
Testing effectiveness (Phase 2)Looking for participantsNCT07492394What this trial is testingDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast CancerWho this might be right forBreast Cancer Hebei Medical University Fourth Hospital 60
Early research (Phase 1)Study completedNCT01245205What this trial is testingAkt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerWho this might be right forHER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Study completedNCT02273973What this trial is testingNeoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)Who this might be right forBreast Cancer Genentech, Inc. 334
Testing effectiveness (Phase 2)Study completedNCT00191373What this trial is testingA Trial for HER2 Positive Breast Cancer Patients With Metastatic DiseaseWho this might be right forBreast NeoplasmsCancer of the BreastBreast Cancer Eli Lilly and Company 66
Large-scale testing (Phase 3)Looking for participantsNCT06195709What this trial is testingECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer PatientsWho this might be right forBreast Carcinoma Institut Curie 300
Testing effectiveness (Phase 2)Study completedNCT03054363What this trial is testingTucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast CancerWho this might be right forBreast Cancer University of Colorado, Denver 42